Zynex Kapitalrendite
Was ist das Kapitalrendite von Zynex?
Kapitalrendite von Zynex, Inc. ist 26.05%
Was ist die Definition von Kapitalrendite?
Die Eigenkapitalrendite ist ein Maß für die Rentabilität eines Unternehmens im Verhältnis zum Buchwert des Eigenkapitals. Sie wird berechnet, indem das Nettoergebnis des Geschäftsjahres durch das gesamte Eigenkapital geteilt wird.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Kapitalrendite von Unternehmen in Health Care Sektor auf XETRA im Vergleich zu Zynex
Was macht Zynex?
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. The company also supplies electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products; and distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers CM-1500, a blood volume monitor device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Unternehmen mit kapitalrendite ähnlich Zynex
- Evolve Transition Infrastructure LP hat Kapitalrendite von 26.02%
- Rushil Decor hat Kapitalrendite von 26.02%
- Tortoise Pipeline & Fund Inc hat Kapitalrendite von 26.03%
- RingCentral hat Kapitalrendite von 26.03%
- Bleecker Societe Anonyme hat Kapitalrendite von 26.04%
- The Brighton Pier PLC hat Kapitalrendite von 26.05%
- Zynex hat Kapitalrendite von 26.05%
- TCI Express hat Kapitalrendite von 26.07%
- SelfWealth hat Kapitalrendite von 26.08%
- Pushpay hat Kapitalrendite von 26.08%
- HDFC Asset Management hat Kapitalrendite von 26.08%
- Bayer CropScience hat Kapitalrendite von 26.09%
- Jindal Worldwide hat Kapitalrendite von 26.11%